In five cases, the isolated variants also allowed prioritization of the drugs to be used in order to alleviate symptoms (in the three patients with CACNA1A point mutations, acetazolamide followed by verapamil, valproic acid, and gabapentin were used; in KNCH1 channelopathy benzodiazepines and levetiracetam were tried; and in SCN4A mutation a sodium channel locker like mexiletine has been offered). The gene discussed is CACNA1A; the disease is channelopathy.